NCT07635862
Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism
Not Yet Recruiting
PHASE2Ages 5–17InterventionalTreatmentStanford UniversityInvestigator-initiated
~66 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Ganaxolone (Ztalmy)Placebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The score on irritability subscale on the Aberrant Behavior Checklist (ABC)
Measured over The measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.
Conditions
NCT07635862
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Stanford University
Stanford, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Antonio Y. Hardan, M.D. · PRINCIPAL_INVESTIGATOR · Stanford University School of Medicine-Psychiatry and Behavioral Sciences - Child and Adolescent Psychiatry and Child Development
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The score on irritability subscale on the Aberrant Behavior Checklist (ABC)The measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.
It is a common symptom of emotion dysregulation in ASD that impacts quality of life, including mental health, independence, educational opportunities, and integration into the community, and ganaxolone may provide more direct benefits or increased tolerability compared to atypical antipsychotics.